Table 1 Basic characteristics of patients
Characteristics | N |
|---|---|
Sex | Â |
Female | 257(55.7%) |
Male | 204(44.3%) |
Age (years) | Â |
< 60 | 260(56.4%) |
≥ 60 | 201(43.6%) |
Stage | Â |
IVA | 259(56.2%) |
IVB or IVC | 202(43.8%) |
Smoking status | Â |
No | 317(68.8%) |
Yes | 144(31.2%) |
Hypertension | Â |
No | 361(78.3%) |
Yes | 100(21.7%) |
Diabetes | Â |
No | 439(95.2%) |
Yes | 22(4.8%) |
Coronary disease | Â |
No | 441(95.7%) |
Yes | 20(4.3%) |
Pathology type | Â |
Adenocarcinoma | 444(96.3%) |
Non-adenocarcinoma | 17(3.7%) |
EGFR mutation | Â |
19del | 242(52.5%) |
L858R | 183(39.7%) |
Other mutations | 36(7.8%) |
Pleural metastasis | Â |
No | 329(71.4%) |
Yes | 132(28.6%) |
Liver metastasis | Â |
No | 433(93.9%) |
Yes | 28(6.1%) |
Brain metastasis | Â |
No | 363(78.7%) |
Yes | 98(21.3%) |
Bone metastasis | Â |
No | 285(61.8%) |
Yes | 176(38.2%) |
Adrenal gland metastasis | Â |
No | 428(92.8%) |
Yes | 33(7.2%) |
Intrapulmonary metastasis | Â |
No | 319(69.2%) |
Yes | 142(30.8%) |
Malignant pleural effusion | Â |
No | 395(85.7%) |
Yes | 66(14.3%) |
Other metastasis | Â |
No | 420(91.1%) |
Yes | 41(8.9%) |
CEA | Â |
Negative | 157(34.1%) |
Positive | 304(65.9%) |
SCC | Â |
Negative | 398(86.3%) |
Positive | 63(13.7%) |
NSE | Â |
Negative | 286(62.0%) |
Positive | 175(38.0%) |
ProGRP | Â |
Negative | 336(72.9%) |
Positive | 125(27.1%) |
CYFRA 21 − 1 |  |
Negative | 238(51.6%) |
Positive | 223(48.4%) |
EGFR-TKIs | Â |
Osimertinib | 208(45.1%) |
Icotinib | 200(43.4%) |
Gefitinib | 53(11.5%) |
Immunotherapy | Â |
No | 423(91.8%) |
Yes | 38(8.2%) |
Lung surgery | Â |
No | 453(98.3%) |
Yes | 8(1.7%) |
Metastasis surgery | Â |
No | 455(98.7%) |
Yes | 6(1.3%) |
Radiotherapy | Â |
No | 284(61.6%) |
Yes | 177(38.4%) |
Chemotherapy | Â |
No | 257(55.7%) |
Yes | 204(44.3%) |